Skip to content

Correlation between cardiometabolic index and albuminuria in patients with type 2 diabetes

Retrospective analysis of the correlation between cardiometabolic index and albuminuria in patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047930
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes, diabetic nephropathy

Interventions

Gold Standard:1. All patients met the 1999 WHO diagnostic criteria for diabetes: diabetes symptoms (polyuria, polydipsia, polyphagia, and unexplained weight loss due to hyperglycemia) plus random bloo

Sponsors

Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. All patients met the 1999 WHO diagnostic criteria for diabetes: diabetes symptoms (polyuria, polydipsia, polyphagia, and unexplained weight loss due to hyperglycemia) plus random blood glucose >= 11.1 mmol/L or fasting blood glucose >= 7 mmol/L or 75 g glucose tolerance test 2 hours postprandial blood glucose >= 11.1 mmol/L. 2. Diagnosis of patients with diabetic albuminuria: in line with the diagnostic criteria in the ''Chinese Clinical Guidelines for the Prevention and Treatment of Diabetic Kidney Diseases (2019 Edition)'', the average of two urine albumin/creatinine >= 30 mg/g, and exclude the increase of urinary albumin caused by other diseases.

Exclusion criteria

Exclusion criteria: 1. Acute complications of diabetes, kidney diseases caused by primary or secondary nephritis, urinary tract infection, acute and chronic renal failure, etc.; 2. Severe liver and heart dysfunction; 3. Acute infection, immunodeficiency, tumor; 4. Use of lipid-lowering drugs and/or angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARBs) in the past 3 months.

Design outcomes

Primary

MeasureTime frame
cardiometabolic index;

Countries

China

Contacts

Public ContactWan Qin

Affiliated Hospital of Southwest Medical University

wanqin3@163.com+86 13882746971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026